scholarly journals Radiotherapy for Metastatic Merkel Cell Carcinoma: A Review of the Literature

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Luluel Khan ◽  
Elizabeth A. Barnes
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Case Reports ◽  
Case Series ◽  
Merkel Cell ◽  
Primary Tumors ◽  
Non Melanoma Skin Cancer ◽  
Retrospective Nature ◽  
Melanoma Skin

Introduction.Merkel cell carcinoma is a rare form of non-melanoma skin cancer of neuroendocrine origin. Optimal management of patients is controversial and the role of radiotherapy is unclear.Purpose.The purpose of this study was to review the efficacy of RT in the treatment of both local and distant metastatic disease from MCC.Methods.A literature search was conducted in MEDLINE (1946—January Week 1 2012) and Embase (1980–2012 Week 2). Articles of interest analyze the efficacy of radiotherapy for treatment of metastatic MCC and did not exclude case reports.Results.All articles except one focusing on the role of radiotherapy were of retrospective origin or case series. Significant limitations applied in all studies due to limited sample sizes and the retrospective nature of these studies. Radiotherapy improves locoregional control in the adjuvant setting, and many series suggest an improvement in overall survival. In cases where surgery is not possible, definitive radiotherapy may be an as-efficacious alternative. The radiosensitive nature of MCC coupled with existing reports suggests that treatment via current protocols for other primary tumors is adequate.Conclusion.Further studies should be conducted prospectively to clarify the true role of radiotherapy in metastatic MCC.

Merkel Cell Carcinoma Guidelines

2006 ◽  
Vol 4 (7) ◽  
pp. 704 ◽  
Keyword(s):  
Skin Cancer ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Treatment Strategies ◽  
Biomedical Literature ◽  
Merkel Cell ◽  
Recurrence Rates ◽  
Non Melanoma Skin Cancer ◽  
Recent Version ◽  
Melanoma Skin

Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative non-melanoma skin cancer with the regional and distant metastatic rates of thick melanoma. The mortality rate of MCC exceeds that of melanoma, and the 5-year disease-specific survival rate is 64%. These guidelines and most biomedical literature suggest that the workup of a patient with MCC should include chest radiograph and additional studies as clinically indicated. These guidelines, which the NCCN Non-Melanoma Skin Cancer Panel developed as a supplement to those for squamous cell and basal cell skin cancer, also outline treatment strategies. For the most recent version of the guidelines, please visit NCCN.org

scholarly journals Merkel Cell Carcinoma and Diagnostic Experience in a Reference Hospital: A Case Series

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Rocio del Pilar López Panqueva ◽  
David A. Suarez-Zamora ◽  
Luis E. Barrera-Herrera ◽  
Mariam Rolón Cadena
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Case Reports ◽  
Case Series ◽  
Recurrence Risk ◽  
Cross Sectional Study ◽  
University Hospital ◽  
Merkel Cell ◽  
Cross Sectional ◽  
Exposed Skin

Merkel cell carcinoma (MCC) is a rare poorly differentiated neuroendocrine tumor, usually located in sun-exposed skin, with aggressive behavior and with high recurrence risk and metastatic disease. In Latin America, case series have been published, and it does not exceed 32 patients in 10 years, and in Colombia, there are case reports. We present a descriptive retrospective cross-sectional study in patients diagnosed with MCC in the Department of Pathology and Laboratories at the University Hospital Fundación Santa Fe de Bogotá(FSFB) between January 2003 and December 2018. We present the demographic, clinical, and pathological variables of these patients, as well as a literature review.

scholarly journals Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma

2021 ◽  
Vol 22 (4) ◽  
Author(s):  
Enrico Zelin ◽  
Iris Zalaudek ◽  
Marina Agozzino ◽  
Caterina Dianzani ◽  
Arianna Dri ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Checkpoint Inhibitors ◽  
Locally Advanced ◽  
Merkel Cell ◽  
Non Melanoma Skin Cancer ◽  
Skin Cancers ◽  
Multiple Basal Cell Carcinomas ◽  
Melanoma Skin

Opinion statementRecently introduced systemic therapies for locally advanced and metastatic non-melanoma skin cancers (NMSCs) are paving the way for neoadjuvant approach. Although none of the therapeutic options has currently gained indication in this setting, neoadjuvant approach for NMSCs is an open field and we are likely to see huge developments in the near future. Targeted therapy with sonic hedgehog pathway inhibitors is very effective in locally advanced or multiple basal cell carcinomas while immunotherapy with immune checkpoint inhibitors appears to be promising for advanced cutaneous squamous cell carcinoma and Merkel cell carcinoma. To date, targeted therapy and immunotherapy represent the frontiers in NMSC therapeutic management and, according to recent studies, good results can be achieved.

The essential role of radiation therapy in securing locoregional control of merkel cell carcinoma

1990 ◽  
Vol 19 (3) ◽  
pp. 583-591 ◽  
Author(s):  
William H. Morrison ◽  
Lester J. Peters ◽  
Elvio G. Silva ◽  
Charles D. Wendt ◽  
K.Kian Ang ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Essential Role ◽  
Locoregional Control ◽  
Merkel Cell

scholarly journals Immunotherapy in Merkel cell carcinoma: role of Avelumab

2018 ◽  
Vol Volume 7 ◽  
pp. 15-19 ◽  
Author(s):  
Amruth Palla ◽  
Donald Doll
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Merkel Cell

scholarly journals Regionally Metastatic Merkel Cell Carcinoma Associated with Paraneoplastic Anti-N-methyl-D-aspartate Receptor Encephalitis

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Sophia Z. Shalhout ◽  
Kevin S. Emerick ◽  
Peter M. Sadow ◽  
Jenny J. Linnoila ◽  
David M. Miller
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Psychiatric Symptoms ◽  
Checkpoint Inhibitors ◽  
Case Reports ◽  
Intensity Modulated Radiation Therapy ◽  
Sun Exposure ◽  
Merkel Cell ◽  
Paraneoplastic Encephalitis ◽  
Aspartate Receptor

Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine cancer with a high risk of recurrence and metastasis. MCC is generally associated with advanced age, fair skin, sun exposure, immunosuppression, and in the majority of cases, the Merkel cell polyomavirus. Neuroendocrine malignancies are associated with a variety of paraneoplastic neurological syndromes (PNS), characterized as autoimmune responses to malignancy-associated expression of neural antigens. Our literature review underscores previous case reports of MCC-associated PNS with voltage-gated calcium channel (VGCC) and anti-Hu (or ANNA-1) autoantibodies. We present the case of a 59-year-old male with regionally metastatic Merkel cell carcinoma complicated by the paraneoplastic manifestation of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. His primary lower neck subcutaneous MCC and metastasis were initially treated with surgery. Additional recurrent lymph node metastases were successfully treated with definitive intensity-modulated radiation therapy. His PNS improved with rituximab therapy. Although rare, this case highlights that in the setting of seizures and prominent psychiatric symptoms accompanying an MCC diagnosis, evaluation for autoimmune paraneoplastic encephalitis is warranted. Awareness and detection of preexisting PNS are crucial in the era of immune checkpoint inhibitors (ICI) for advanced MCC, where treatment with ICI has the potential to exacerbate preexisting autoimmune PNS and lead to worsened or even lethal neurologic immune-related adverse events (nirAEs).

scholarly journals A Practical Update of Surgical Management of Merkel Cell Carcinoma of the Skin

ISRN Surgery ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-17 ◽  
Author(s):  
Patricia Tai
Keyword(s):  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Recurrent Disease ◽  
Case Reports ◽  
Multimodality Treatment ◽  
Future Research ◽  
Merkel Cell ◽  
Recommended Treatment ◽  
Nodal Dissection

The role of surgeons in the treatment of Merkel cell carcinoma (MCC) of the skin is reviewed, with respect to diagnosis and treatment. Most of the data in the literature are case reports. Surgery is the mainstay of treatment. A wide local excision, with sentinel node (SLN) biopsy, is the recommended treatment of choice. If SLN is involved, nodal dissection should be performed; unless patient is unfit, then regional radiotherapy can be given. Surgeons should always refer patients for assessment of the need for adjuvant treatments. Adjuvant radiotherapy is well tolerated and effective to minimize recurrence. Adjuvant chemotherapy may be considered for selected node-positive patients, as per National Comprehensive Cancer Network guideline. Data are insufficient to assess whether adjuvant chemotherapy improves survival. Recurrent disease should be treated by complete surgical resection if possible, followed by radiotherapy and possibly chemotherapy. Generally results of multimodality treatment for recurrent disease are better than lesser treatments. Future research should focus on newer chemotherapy and molecular targeted agents in the adjuvant setting and for gross disease.

scholarly journals Pembrolizumab as first line treatment of Merkel cell carcinoma patients – a case series of patients with various co-morbidities

2020 ◽  
Vol 59 (7) ◽  
pp. 793-796 ◽  
Author(s):  
Tessa Bystrup Boyles ◽  
Mette Schødt ◽  
Helle Westergren Hendel ◽  
Anders Krarup-Hansen ◽  
Niels Junker
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Case Series ◽  
Line Treatment ◽  
Merkel Cell ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document